ArticleScientific reports2026
Integrating retinal and brain imaging biomarkers for diagnosis of parkinson's disease: findings from a time-lagged cross-sectional persian cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a multisystem neurodegenerative disorder with both central and peripheral manifestations. This study aimed to comprehensively characterize structural and functional alterations in the retina and brain, as well as systemic blood biomarkers, in patients with clinically diagnosed PD compared with healthy controls, using a multimodal imaging approach. Blood-derived biomarkers and OCT data were collected from 29 PD patients and 25 healthy participants over an average interval of 2.7 years. MRI scans were performed using a Philips 1.5 Tesla scanner. Retinal and brain structural and perfusion metrics were analyzed using linear regression models adjusted for age, with statistical significance determined through false discovery rate (FDR) correction. The diagnostic performance was assessed using logistic regression, LASSO-penalized logistic regression model and ROC curve analysis. The study indicated that reduced ALT serum is the only significant hematological marker (p = 0.0253). Structural MRI revealed significant volume reductions in the left amygdala and caudate (p = 0.0241 and 0.0035 respectively); However, these findings necessitate careful interpretation due to limitations in spatial resolution. Perfusion MRI showed lower cerebral blood flow in gray matter and the whole brain (p = 0.02) in PD patients. The best imaging biomarker (PCASL total CBF) achieved an AUC of 0.79. A LASSO-penalized logistic regression model integrating left amygdala volume, left caudate volume, and SGPT achieved a significantly elevated AUC of 0.954, with 100% sensitivity and 86.7% specificity. The integration of central and peripheral biomarkers encompasses complementary aspects of Parkinson's disease pathology, providing a more comprehensive diagnostic framework than any singular modality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.